Nuwellis Awarded U.S. Patent for Catheter Tech That Enhances Extracorporeal Therapies

Nuwellis Inc.’s Dual Lumen Catheter has scored another U.S. patent.

The peripheral dual-lumen catheter is used for extracorporeal therapies, including ultrafiltration, dialysis, and continuous renal replacement therapy (CRRT) modalities. U.S. Patent No. 12,678,592 further expands Nuwellis’ intellectual property portfolio and supports its broader strategy of advancing differentiated technologies across the heart-kidney continuum, according to executives.

The new patent from the U.S. Patent and Trademark Office helps Nuwellis address a longstanding clinical challenge associated with extracorporeal therapies. During treatment, negative pressure generated by blood pumps can cause catheter collapse, reducing blood flow and impacting therapy performance. Nuwellis’ patented design incorporates a reinforcing stainless-steel coil that helps maintain catheter patency under negative pressure while introducing a design that allows clinicians to trim the catheter to an appropriate length for individual patients without compromising its structural integrity. The ability to customize catheter length while maintaining resistance to collapse may improve achievable blood flow, support longer extracorporeal filter life, and provide greater flexibility when treating patients of varying sizes.

“Effective vascular access is fundamental to the performance of extracorporeal therapies,” Nuwellis CEO Mike McCormick said. “This patent represents another example of our commitment to developing practical innovations that address real-world clinical challenges. By combining resistance to catheter collapse with the ability to customize catheter length for individual patients, this technology can improve therapy performance and provide clinicians with greater flexibility across a broad range of patient populations.”

The Aquadex SmartFlow System is indicated for continuous ultrafiltration therapy for temporary (up to eight hours) or extended (longer than eight hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more, whose fluid overload is unresponsive to medical management, including diuretics.

Nuwellis Inc. is a medical technology company delivering solutions for patients with cardiorenal conditions. The company develops solutions that support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations.